Shares of Marrone Bio Innovations (NASDAQ:MBII) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $2.18.
A number of research analysts recently commented on MBII shares. BidaskClub lowered shares of Marrone Bio Innovations from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research lowered shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright set a $4.00 price target on shares of Marrone Bio Innovations and gave the company a “buy” rating in a research note on Thursday, December 21st. Jefferies Group reiterated a “hold” rating and issued a $1.55 price target on shares of Marrone Bio Innovations in a research note on Wednesday, March 21st. Finally, ValuEngine lowered shares of Marrone Bio Innovations from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st.
In related news, insider Ardsley Advisory Partners purchased 6,666,667 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were acquired at an average price of $0.75 per share, for a total transaction of $5,000,000.25. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.80% of the stock is currently owned by corporate insiders.
Marrone Bio Innovations (NASDAQ:MBII) last released its quarterly earnings data on Thursday, March 29th. The basic materials company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $3.32 million for the quarter. research analysts expect that Marrone Bio Innovations will post -0.14 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/12/marrone-bio-innovations-mbii-receives-consensus-rating-of-hold-from-analysts.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.